Related Experiment Videos
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding
1Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA.
Journal of Virology
|May 9, 2000
Summary
The human immunodeficiency virus type 1 (HIV-1) Gag precursor binds efficiently to membranes even without strong Gag-Gag interactions. This suggests matrix and capsid domains are key for initial membrane binding during virus assembly.
Area of Science:
- Virology
- Molecular Biology
- Structural Biology
Background:
- The human immunodeficiency virus type 1 (HIV-1) Gag precursor, Pr55(Gag), drives viruslike particle assembly and release.
- Membrane binding and Gag-Gag multimerization are critical for HIV-1 assembly but their underlying domains and relationships are not fully understood.
Purpose of the Study:
- To investigate the domains responsible for HIV-1 Gag membrane binding and multimerization.
- To elucidate the relationship between membrane binding and Gag-Gag interactions during virus assembly.
Main Methods:
- Analysis of C-terminally truncated HIV-1 Gag mutants (MAstop, CA146stop, p41stop, p43stop, NC35stop) in vivo.
- Assessment of viruslike particle assembly, release, and copackaging with full-length Gag.
- Membrane flotation centrifugation to determine membrane-binding properties.
Main Results:
- Truncated Gag incorporation increased with extension from CA146 to NC35, indicating multiple Gag multimerization sites.
- The MA-only fragment showed reduced membrane binding compared to full-length Gag.
- The CA146 mutant (matrix and N-terminal capsid domains) exhibited membrane-binding levels similar to full-length Pr55(Gag).
Conclusions:
- Efficient HIV-1 Gag membrane binding can occur independently of strong Gag-Gag interaction domains.
- The matrix and N-terminal capsid domains of Gag are sufficient for effective steady-state membrane binding.
- These findings refine our understanding of the initial steps in HIV-1 particle formation.